Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01456481 · ClinicalTrials.gov registry record · Phase 4
Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV
A Phase 4 study of Vasovagal Syncope, sponsored by Dr. Bob Sheldon.
- Active
- Registry status
- Phase 4
- Development phase
- 134
- Enrollment target
- 17
- Study locations
NCT01456481: Active Phase 4 study of Vasovagal Syncope, sponsored by Dr. Bob Sheldon.
NCT01456481 is a Phase 4 study of Vasovagal Syncope that is active but no longer recruiting, run by Dr. Bob Sheldon. The registered enrollment target is 134 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower). The trial reports 17 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01456481, a Phase 4 study of Vasovagal Syncope, is active but no longer recruiting, sponsored by Dr. Bob Sheldon.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 134 participants
- Enrollment target
- 17
- Study locations
Study Summary
About 20% of adults faint recurrently. These patients are often highly symptomatic, have problems with employment and driving and have reduced quality of life. There are no therapies that have withstood the test of adequately designed and conducted randomized clinical trials. Midodrine is a prodrug whose metabolite is an alpha-1 adrenergic agonist that increases venous return to the heart and raises blood pressure. There is considerable lower level evidence that it might prevent vasovagal syncope. The investigators will test the hypothesis that Midodrine prevents recurrences of syncope in patients with moderate to severe vasovagal syncope.
Conditions Studied
Interventions
- DRUG matching placebo
- DRUG midodrine hydrochloride
Study Locations (17)
Alberta
- University of Calgary - Calgary
- Alberta Health Services - Royal Alexandra Hospital - Edmonton
- Royal Alexandra Hospital - Edmonton
- Red Deer Regional Hospital - Red Deer
Ontario
- Hamilton Health Sciences - Hamilton
- University of Ottawa Heart Institute - Ottawa
Quebec
- Hopital Sacre Coeur de Montreal - Montreal
- Centre Hospitalier Universitaire de Sherbrooke - Sherbrooke
Saskatchewan
- Prairie Vascular Research Network/Regina General Hospital - Regina
- Saskatoon Cardiology Consultants/Royal University Hospital - Saskatoon
Minnesota
- University of Minnesota - Minneapolis
Tennessee
- Vanderbilt University - Nashville
British Columbia
- Victoria Cardiac Arrythmia Trials - Victoria
Manitoba
- St. Boniface General Hospital - St. Boniface
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2011-11 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 4 |
What the registry record for NCT01456481 still lists
NCT01456481 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Vasovagal Syncope appearing as the primary indexed condition, and to 2 interventions - of which matching placebo is the first listed.
NCT01456481 lists 17 locations in 11 states (Alberta, Ontario, Quebec).
Frequently Asked Questions
What is clinical trial NCT01456481 about?
NCT01456481 is a clinical study titled "Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV". About 20% of adults faint recurrently. These patients are often highly symptomatic, have problems with employment and driving and have reduced quality of life. There are no therapies that have withstood the test of adequately designed and conducted randomized clinical trials. Midodrine is a prodrug ...
What is the current status of trial NCT01456481?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 134 participants. The study started on 2011-11. Estimated completion is 2024-12-31.
What conditions does trial NCT01456481 study?
This clinical trial studies the following conditions: Vasovagal Syncope.
What interventions are being tested in trial NCT01456481?
The interventions under investigation include: matching placebo (DRUG), midodrine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01456481?
This trial is sponsored by Dr. Bob Sheldon, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01456481 being conducted?
This trial has 17 study locations across Minnesota, Tennessee, Alberta, British Columbia, Manitoba. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vasovagal Syncope
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01456481's enrollment target sits among peer trials
134 606th of 2000 higher than 1,392 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia